Company Active LTD

Company profile

Mironid Limited

Bot Verification

Mironid Limited is a UK company with status active founded in 2014.

CRN
SC476430
Founded
2014
Age
12

Overview

Legal name
MIRONID LIMITED
Region
Unknown
Registered address
ARBUTHNOTT BUILDING (HAMNETT WING)
161 CATHEDRAL STREET
GLASGOW
SCOTLAND
G4 0RE
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

9 events
30 Nov
2026

Accounts due

Accounts Due

Next accounts due date

04 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

29 May
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUyNDMzNzc5NWFkaXF6a2N4

Published 29 May 2026 15:02

10 Apr
2026

Resolution

Resolution

RESOLUTIONS | Transaction WUVaUDBZOVNhZGlxemtjeA | Paper/PDF filed

Published 10 Apr 2026 13:24

20 Sep
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

28 Feb
2025

Accounts filed

Accounts

Last accounts made up date

30 Sep
2024

Accounts With Accounts Type Small

Accounts PDF pending

AA | Transaction MzQzNzY4NzkzMmFkaXF6a2N4 | Paper/PDF filed

Published 02 Oct 2024 06:15

30 Sep
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzNzY3NjQ3MGFkaXF6a2N4

Published 30 Sep 2024 08:04

29 Apr
2014

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2017
Funded years
2017, 2018, 2023
Age at first award
2 years

Projects

2023 Collaborative R&D Lead participant

Extending Mironid's PDE4 activator programme: Hyperparathyroidism as a second clinical indication

1 Mar 2023 to 29 Feb 2024

Awarded
£501,892
Total cost £716,988

Human parathyroid hormone (PTH) is produced by four parathyroid glands located in the neck and regulates the level of calcium and phosphate in the blood by controlling reabsorption from urine, uptake from the digestive tract and resorption from calcium reservoirs in the bone. Hyperparathyroidism results in excessive release of parathyroid hormone into the...

2018 Feasibility Studies Lead participant

Small molecule activators of cAMP PDE4 long isoforms for immuno-oncology

1 Apr 2018 to 30 Jun 2019

Awarded
£135,066
Total cost £192,951

According to the World Health Organisation 8.8 million people died of cancer in 2015: 1 in 6 of all global deaths. Tumours are able to hide from the immune system, avoiding detection and removal by the body's natural defences. The ability to reveal tumours to the immune system by overcoming cloaking processes, the core of immuno-oncology, is showing great...

2017 Collaborative R&D Lead participant

Small molecule activators of cAMP PDE4 long isoforms for the treatment of ADPKD

1 Jan 2017 to 30 Sep 2017

Awarded
£424,678
Total cost £606,683

Autosomal dominant polycystic kidney disease (ADPKD) is a life-threatening and currently incurable genetic disorder of the kidneys characterised by the development of pathological cysts. It affects some 12.5 million people worldwide, with around 50% of sufferers requiring treatment for kidney failure by the age of 60. Mironid is applying its unique unders...

Product types

Collaborative R&D Feasibility Studies